NKF News

Main menu
Contents

Want to see the real deal?
More inside scoop? View in App

My Company

#Polls

Browse by:

Companies

Keywords

Customize Interests

Blog

COMPANY

SUPPORT

Rooftop Slushie Get Referrals to FAANG

DOWNLOAD THE APP:

NKF

4.0 (1 reviews)

REVIEW THIS COMPANY

NKF MedPage Today / Apr 10, 2021

Gout treatment with pegloticase was well tolerated in a dialysis-dependent population, researchers found in a small study. In an analysis of 42 patients with uncontrolled gout currently undergoing routine outpatient dialysis, most received on-label pegloticase (Krystexxa) consisting of biweekly infusions, with a median of three infusions, reported Anthony Bleyer, MD, of Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues.

https://www.medpagetoday.com/meetingcoverage/nkf/92017

Pegloticase Safe for Dialysis Patients With Gout

MedPage Today

NKF Healio / Apr 10, 2021

Among patients awaiting a renal transplant, Black and white women experienced unequal access to wait lists compared with white men, according to presented data.

https://www.healio.com/news/nephrology/20210410/black-white-women-with-eskd-experience-reduced-transplant-access

Black, white women with ESKD experience reduced transplant access

Healio

NKF Healio / Apr 10, 2021

While not without flaws, opt-out laws that presume citizens will donate organs have expanded the donor pool in Europe and provide lessons for the United States, said a speaker at the National Kidney Foundation Spring Clinical Meetings.“In the U.S., no organs are recovered from many potential older donors, perhaps because of the perception of a low probability that any transplant program

https://www.healio.com/news/nephrology/20210410/speaker-lessons-can-be-learned-from-europe-on-how-to-expand-organ-donor-pool

Speaker: Lessons can be learned from Europe on how to expand organ donor pool

Healio

NKF PRNewswire / Apr 9, 2021

NEW YORK, April 9, 2021 /PRNewswire/ -- Each year the National Kidney Foundation (NKF) considers the work of hundreds of specialists, advocates and volunteers in the field of nephrology and selects among them those who most exemplify the relentless efforts of NKF to enhance the lives of patients through action, education, and accelerating change.

https://www.prnewswire.com/news-releases/national-kidney-foundation-honors-doctors-scientists-volunteer-public-servant-with-awards-at-annual-spring-clinical-meetings-301265651.html

National Kidney Foundation Honors Doctors, Scientists, Volunteer, Public Servant with Awards at Annual Spring Clinical Meetings

PRNewswire

NKF MedPage Today / Apr 9, 2021

Artificial intelligence was predictive of care strategies for patients with diabetic kidney disease, a new study found. Test results from the KidneyIntelX diagnostic tool were significantly tied to how a primary care physician tailored a patient's treatment strategy, reported Manasi Datar, PhD, of Boston Healthcare Associates in Massachusetts, and colleagues.

https://www.medpagetoday.com/meetingcoverage/nkf/92006

Diabetic Kidney Disease Risk Stratifier Helpful Tool for PCPs

MedPage Today

NKF Renal and Urology News / Apr 9, 2021

Onset of end-stage kidney disease (ESKD) in patients with autosomal dominant polycystic kidney disease (ADPKD) occurs earlier in Hispanic patients than in those of other races, according to study findings presented at the virtual National Kidney Foundation 2021 Spring Clinical Meetings. In a study of 3868 patients with ADPKD, Teresa N.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/kidney-failure-autosomal-dominant-polycystic-kidney-diseases-racial-ethnic-differences/

ADPKD Progression to End-Stage Kidney Disease Varies by Race/Ethnicity

Renal and Urology News

NKF Renal and Urology News / Apr 9, 2021

Sodium bicarbonate, which is commonly used to treat metabolic acidosis in patients with chronic kidney disease (CKD), is hypothesized to increase the risk for calcium phosphate kidney stones by increasing urinary pH.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/sodium-bicarbonate-effects-on-calcium-phosphate-citrate-nephrolithiasis/

Sodium Bicarbonate May Mitigate Calcium Phosphate Stone Risk in CKD

Renal and Urology News

NKF Renal and Urology News / Apr 9, 2021

Preemptive therapeutic plasma exchange (TPE) and rituximab treatment may lower the risk of recurrence of focal segmental glomerulosclerosis (FSGS) in kidney transplant recipients, according to study findings presented at the virtual National Kidney Foundation 2021 Spring Clinical Meetings.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/therapeutic-plasma-exchange-rituximab-fsgs-kidney-transplant-patients/

Preemptive Therapy May Stop FSGS Recurrence in Kidney Transplant Recipients

Renal and Urology News

NKF MedPage Today / Apr 9, 2021

Gout treatment with pegloticase was well tolerated in a dialysis-dependent population, researchers found in a small study. In an analysis of 42 patients with uncontrolled gout currently undergoing routine outpatient dialysis, most received on-label pegloticase (Krystexxa) consisting of biweekly infusions, with a median of three infusions, reported Anthony Bleyer, MD, of Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues.

https://www.medpagetoday.com/meetingcoverage/nkf/92017

Pegloticase Safe for Dialysis Patients With Gout

MedPage Today

NKF Renal and Urology News / Apr 9, 2021

Among Black patients with COVID-19, those who have the apolipoprotein L1 (APOL1) high-risk genotype are at increased risk for acute kidney injury (AKI), new findings presented at the virtual National Kidney Foundation 2021 Spring Clinical Meetings suggest.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/apolipoprotein-1-genotype-covid-19-aki-risk-black-patients/

APOL1 High-Risk Genotype Increases COVID-19-Related AKI Risk in Blacks

Renal and Urology News

NKF Renal and Urology News / Apr 9, 2021

Approximately one-third of hospitalized patients with hyperkalemia receive potassium binders, with differential use of sodium polystyrene sulfonate (SPS), patiromer, and sodium zirconium cyclosilicate (SZC), investigators reported at the virtual National Kidney Foundation 2021 Spring Clinical Meetings.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/hospital-prescriptions-sodium-polystyrene-sulfonate-patiromer-sodium-zirconium-cyclosilicate/

Potassium Binder Use Among Hospitalized Patients With Hyperkalemia

Renal and Urology News

NKF Medscape / Apr 9, 2021

Difelikefalin, an investigational intravenous (IV) drug for treating itch (pruritus) in patients with end-stage renal disease on hemodialysis, was safe and effective in two parallel pivotal trials in which 796 patients on dialysis received the drug.

https://www.medscape.com/viewarticle/949033

Difelikefalin Safe, Effective for Kidney Disease-Associated Pruritus

Medscape

NKF Healio / Apr 9, 2021

A national survey shows patients on dialysis who are hesitant about taking a vaccine for COVID-19 share similar characteristics to those in the general public with the same views, a speaker said.Overall, however, a higher percentage of patients on dialysis are in favor of being vaccinated vs.

https://www.healio.com/news/nephrology/20210409/similar-characteristics-seen-in-patients-with-eskd-public-who-question-covid19-vaccine

Healio

NKF Healio / Apr 9, 2021

Among patients with chronic kidney disease, use of in-person services was dramatically reduced during the early months of COVID-19 pandemic, which was followed by an incomplete rebound, according to presented data.“Telehealth helped, but it only partially compensated for the reduction that we saw in utilization,” Clarissa Jonas Diamantidis, MD, MHS, said during her presentation at the

https://www.healio.com/news/nephrology/20210409/study-covid19-pandemic-significantly-reduced-ckd-care-management

Study: COVID-19 pandemic significantly reduced CKD care management

Healio

NKF Healio / Apr 9, 2021

Although most insurance providers, including Medicare and private insurers, cover medical nutrition therapy for individuals with chronic kidney disease, few patients ever meet with a registered dietician. Holly Kramer, MD, MPH, of Loyola University Chicago, attributes low use of the therapy to a lack of awareness on the part of medical providers and registered dieticians.

https://www.healio.com/news/nephrology/20210409/insurance-covers-ckd-nutrition-therapy-but-many-medical-providers-and-dieticians-unaware

Insurance covers CKD nutrition therapy, but many medical providers and dieticians unaware

Healio

NKF PRNewswire / Apr 8, 2021

" COVID-19 has particularly ravaged patients with kidney disease in Black, Hispanic and other minority communities," said NKF President Paul Palevsky, MD. "We look forward to Dr. Maybank's insights into ensuring greater racial equity in healthcare as NKF increases its focus on eliminating disparities in the care of patients with kidney disease."

https://www.prnewswire.com/news-releases/dr-maybank-to-be-keynote-speaker-at-annual-gathering-of-kidney-care-professionals-301265034.html

Dr. Maybank to be Keynote Speaker at Annual Gathering of Kidney Care Professionals

PRNewswire

NKF Renal and Urology News / Apr 8, 2021

In-person visits among patients last known to have stage 3 to 4 chronic kidney disease (CKD) declined dramatically early in the COVID-19 pandemic compared with usual levels, and telehealth did not fully compensate for the loss in medical care, investigators revealed during the virtual National Kidney Foundation 2021 Spring Clinical Meetings.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/sars-cov-2-pandemic-in-person-visits-telehealth-medical-care-chronic-kidney-disease/

Decline in Advanced CKD Care Observed During COVID-19 Pandemic

Renal and Urology News

NKF Renal and Urology News / Apr 8, 2021

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), successfully treats anemia in patients with chronic kidney disease (CKD), including those initiating or continuing dialysis therapy, according to updated findings presented during the virtual National Kidney Foundation 2021 Spring Clinical Meetings.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/roxadustat-hif-phi-hemoglobin-iron-transfusion-in-anemia-ckd-dialysis/

Study: Roxadustat Effectively Treats Anemia Across CKD Stages

Renal and Urology News

NKF Renal and Urology News / Apr 8, 2021

Despite the progress in autosomal dominant polycystic kidney disease (ADPKD) management, patients continue to experience challenges, according to new research presented virtually during the National Kidney Foundation 2021 Spring Clinical Meetings.

https://www.renalandurologynews.com/home/conference-highlights/national-kidney-foundation-annual-meeting/nkf-2021-spring-meeting/autosomal-dominant-polycystic-kidney-disease-patient-experiences-symptoms-diagnosis/

Patient Interviews Highlight Challenges in ADPKD Management

Renal and Urology News

NKF Business Wire / Apr 8, 2021

VICTORIA, British Columbia & ROCKVILLE, Md.--()-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) todaypresented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D.

https://www.businesswire.com/news/home/20210408005099/en/Aurinia-Presents-Data-Demonstrating-LUPKYNIS%E2%84%A2-voclosporin-Efficacy-Across-Lupus-Nephritis-Biopsy-Classes-at-National-Kidney-Foundation-2021-Spring-Clinical-Meetings

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

Business Wire

03 04 05 06 07

FOLLOW US

My Company

#Polls

Companies

Keywords

FOLLOW US

NKF News

Among patients awaiting a renal transplant, Black and white women experienced unequal access to wait lists compared with white men, according to presented data.

Sodium bicarbonate, which is commonly used to treat metabolic acidosis in patients with chronic kidney disease (CKD), is hypothesized to increase the risk for calcium phosphate kidney stones by increasing urinary pH.

Preemptive therapeutic plasma exchange (TPE) and rituximab treatment may lower the risk of recurrence of focal segmental glomerulosclerosis (FSGS) in kidney transplant recipients, according to study findings presented at the virtual National Kidney Foundation 2021 Spring Clinical Meetings.

Among Black patients with COVID-19, those who have the apolipoprotein L1 (APOL1) high-risk genotype are at increased risk for acute kidney injury (AKI), new findings presented at the virtual National Kidney Foundation 2021 Spring Clinical Meetings suggest.

Difelikefalin, an investigational intravenous (IV) drug for treating itch (pruritus) in patients with end-stage renal disease on hemodialysis, was safe and effective in two parallel pivotal trials in which 796 patients on dialysis received the drug.

A national survey shows patients on dialysis who are hesitant about taking a vaccine for COVID-19 share similar characteristics to those in the general public with the same views, a speaker said.Overall, however, a higher percentage of patients on dialysis are in favor of being vaccinated vs.

Despite the progress in autosomal dominant polycystic kidney disease (ADPKD) management, patients continue to experience challenges, according to new research presented virtually during the National Kidney Foundation 2021 Spring Clinical Meetings.

OPEN IN APP